<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/103</identifier>
				<datestamp>2023-04-11T02:03:34Z</datestamp>
				<setSpec>regsci:RA</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Challenges in the Development of drugs for Systemic Lupus Erythematosus: A Regulatory Perspective</dc:title>
	<dc:creator xml:lang="en">Del Vecchio, Alfred M.</dc:creator>
	<dc:creator xml:lang="en">Chevrier, Marc R.</dc:creator>
	<dc:creator xml:lang="en">Elias, Drew R.</dc:creator>
	<dc:creator xml:lang="en">O'Dowd, Liza C.</dc:creator>
	<dc:creator xml:lang="en">Paxson, Bethany K.</dc:creator>
	<dc:creator xml:lang="en">Rose, Shawn M.</dc:creator>
	<dc:creator xml:lang="en">Shields-Tuttle, Kimberly A.</dc:creator>
	<dc:creator xml:lang="en">Vermeulen, Rob</dc:creator>
	<dc:subject xml:lang="en">Systemic lupus erythematosus</dc:subject>
	<dc:subject xml:lang="en">lupus</dc:subject>
	<dc:subject xml:lang="en">FDA</dc:subject>
	<dc:subject xml:lang="en">EMA</dc:subject>
	<dc:subject xml:lang="en">regulatory guidance</dc:subject>
	<dc:subject xml:lang="en">clinical development</dc:subject>
	<dc:subject xml:lang="en">Review of regulatory guidance</dc:subject>
	<dc:description xml:lang="en">Systemic lupus erythematosus (SLE) is a debilitating disease that affects at least 5 million people worldwide. Currently, there are limited approved treatment options for patients with SLE, and a great need remains for therapies to achieve important treatment goals such as reductions in flares, prevention of organ damage, clinical low disease activity or remission. The purpose of this article is to review the current health authority guidance for the development of drugs to treat SLE and discuss some of the challenges in the development of drugs for SLE from a regulatory perspective. Given the substantial number of failed late-stage clinical trials in this indication despite the inclusion of large numbers of subjects, reviewing the regulatory guidance and complexities surrounding the development of drugs for the treatment of SLE is crucial to understand the complexities of the disease itself and the challenges and limitations to conducting successful trials evaluating the impact of treatment of new agents in SLE. As only one new drug (belimumab, trade name BENLYSTAÂ®) with a novel mechanism of action has been approved over the last six decades, the prescribing information for belimumab will be reviewed in the context of the guidance.https://doi.org/10.21423/jrs-v07delvecchio</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2019-07-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/103</dc:identifier>
	<dc:identifier>10.21423/JRS-V07DELVECCHIO</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol 7 (2019); 1-13</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/103/112</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2019 Journal of Regulatory Science</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
